Exelixis, Inc.

Informe acción NasdaqGS:EXEL

Capitalización de mercado: US$9.9b

Salud financiera de hoja de balance de Exelixis

Salud financiera controles de criterios 6/6

Exelixis tiene un patrimonio de accionistas total de $2.3B y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $3.0B y $684.9M respectivamente. El BAIT de Exelixis es de $608.3M, por lo que su ratio de cobertura de intereses es de -7.9. Tiene efectivo e inversiones a corto plazo que ascienden a $1.2B.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses-7.9x
EfectivoUS$1.19b
PatrimonioUS$2.28b
Total pasivoUS$684.86m
Activos totalesUS$2.96b

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine

Oct 31

Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story

Oct 31
Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story

Here's Why We Think Exelixis (NASDAQ:EXEL) Is Well Worth Watching

Oct 26
Here's Why We Think Exelixis (NASDAQ:EXEL) Is Well Worth Watching

Getting In Cheap On Exelixis, Inc. (NASDAQ:EXEL) Might Be Difficult

Sep 02
Getting In Cheap On Exelixis, Inc. (NASDAQ:EXEL) Might Be Difficult

Exelixis Comes Up Aces

Aug 08

If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

Jun 14
If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

May 24
It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

May 07
Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

Exelixis: With Patent Litigation Decision Due Soon, There Are Options

May 02

Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Apr 22
Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Mar 28

We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Feb 26
We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Jan 17

Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Dec 27
Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

May 30
An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($1.5B) de EXEL superan a sus pasivos a corto plazo ($394.3M).

Pasivo a largo plazo: Los activos a corto plazo de EXEL ($1.5B) superan a sus pasivos a largo plazo ($290.5M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: EXEL está libre de deudas.

Reducción de la deuda: EXEL no tenía deudas hace 5 años.

Cobertura de la deuda: EXEL no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.

Cobertura de intereses: EXEL no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.


Hoja de balance


Descubre empresas con salud financiera